8-K: Sonnet BioTherapeutics Announces Positive Safety Review in Phase 1 SB101 Clinical Trial

Sonnet BioTherapeutics reports positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical trial evaluating SON-1010 in combination with trabectedin for advanced leiomyosarcoma or liposarcoma.

Summary

• Sonnet BioTherapeutics announced positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical trial.
• The trial is evaluating SON-1010, the company's proprietary version of recombinant human interleukin-12 (rhIL-12), in combination with trabectedin for adult patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS).
• The expansion cohort builds on the successful completion of monotherapy dose escalation and assignment of the SON-1010 maximum tolerated dose (MTD) of 1200 ng/kg.
• The SB101 Safety Review Committee (SRC) evaluated the initial status of patients in the expansion cohort, all of whom are receiving the SON-1010/trabectedin combination.
• After an average treatment of slightly over two months, one patient progressed, and the other six are tolerating treatment.
• Adverse events (AEs) considered related to either drug have all been mild or moderate, suggesting that the two drugs do not appear to be adversely impacting each other.
• The annual review including all 30 patients dosed to date showed that common AEs considered related to SON-1010 monotherapy or in combination included fatigue, fever, chills, and myalgia in 15% or more; moderate fatigue was the only related AE in 2 or more of the patients treated with trabectedin to date.
• Five of the six patients in the SON-1010 high-dose monotherapy group (83%) showed stable disease at 4 months, and four continue on trial at 6 months with no new safety concerns.
• One patient in the monotherapy group experienced a partial response (PR), confirming the potential benefit of SON-1010 monotherapy at the MTD.
• Overall, 13 of the 24 patients studied during SON-1010 dose escalation (54%) had evidence of monotherapy clinical benefit.
• The company expects to enroll up to 18 patients with unresectable, metastatic LMS or LPS in this open-label, single-arm expansion cohort.

Sentiment

Score: 7

Explanation: The document presents positive safety data from an ongoing clinical trial, suggesting potential for the drug combination. However, it's important to note that the trial is still in its early stages, and further data is needed to confirm efficacy. The sentiment is cautiously optimistic.

Positives

• The safety review of the expansion cohort in the Phase 1 SB101 trial showed positive findings.
• Six out of seven patients in the expansion cohort are tolerating treatment well.
• Adverse events related to either drug have been mild or moderate.
• A high percentage (83%) of patients in the SON-1010 high-dose monotherapy group showed stable disease at 4 months.
• One patient in the monotherapy group experienced a partial response, indicating potential benefit.
• Over half (54%) of patients studied during SON-1010 dose escalation showed evidence of monotherapy clinical benefit.

Negatives

• One patient in the expansion cohort progressed after an average treatment of slightly over two months.

Risks

• The trial is still ongoing, and further results are needed to confirm the efficacy of the combination therapy.
• Forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially.

Future Outlook

The company expects to enroll up to 18 patients with unresectable, metastatic LMS or LPS in the open-label, single-arm expansion cohort. The full enrollment of the combination cohort will provide an opportunity to evaluate statistical evidence of benefit in the response using the standard RECIST paradigm, which may also confirm synergy.

Management Comments

• The document does not contain any direct quotes from management, but it implies management is optimistic about the initial safety results and the potential for synergy between SON-1010 and trabectedin.

Industry Context

This announcement is relevant to the oncology space, particularly in the treatment of soft-tissue sarcomas. The combination of SON-1010, an IL-12 based therapy, with trabectedin, a chemotherapeutic agent, represents a novel approach to potentially enhance anti-tumor immune responses. Competitors in this space include companies developing other immunotherapies and targeted therapies for sarcomas.

Comparison to Industry Standards

• Trabectedin (Yondelis) is an approved chemotherapeutic drug for advanced soft-tissue sarcomas (STS) after failure of primary therapy, so the trial is building on an existing standard of care.
• The trial is evaluating the potential for synergy between SON-1010 and trabectedin, which could improve outcomes compared to trabectedin alone.
• Other companies developing immunotherapies for sarcomas include those targeting PD-1/PD-L1 and other immune checkpoints.

Stakeholder Impact

• Positive results could benefit patients with advanced leiomyosarcoma or liposarcoma by providing a new treatment option.
• Successful development of SON-1010 could increase shareholder value.
• The trial's progress impacts the company's employees and their work on this project.

Next Steps

• The company expects to enroll up to 18 patients in the expansion cohort.
• The full enrollment of the combination cohort will provide an opportunity to evaluate statistical evidence of benefit in the response using the standard RECIST paradigm.

Key Dates

Keywords

SON-1010, trabectedin, leiomyosarcoma, liposarcoma, SB101 clinical trial, Phase 1 trial, Sonnet BioTherapeutics, clinical trial, cancer, oncology